CD34 and cancer: These clinical data confirmed a distinct pharmacodynamic difference between LY2510924 peptide and LY2624587 antibody in a human cancer patient population, which is consistent with the preclinical results in monkeys: LY2510924 peptide induced a robust, sustained increase in WBCs and CD34+ HSCs, whereas LY2624587 antibody only transiently increased WBCs and had no significant effect on CD34+ HSCs.